Ottawa, May 5, 2025 – The Health Research Foundation (HRF) of Innovative Medicines Canada is pleased to announce that nominations are now open for the 2025 Diversity and Equity in Research Award, celebrating exceptional Canadian researchers who are advancing equitable access to healthcare and inclusive participation in health research.
Now in its third year, the award honours individuals whose work is making a transformative difference for equity-deserving communities across Canada. Past recipients include Dr. Sonia Anand, a trailblazer in cardiovascular research and health equity, who was recognized in 2024 for her work addressing the social and genetic determinants of disease in diverse populations.
“The HRF Diversity and Equity in Research Award is more than recognition—it’s a call to action,” said Christine Elliott, Chair of the HRF Board of Directors. “We are proud to spotlight those who are dismantling barriers in the healthcare system and ensuring no one is left behind in Canada’s research landscape.”
The recipient of the 2025 award will be honoured at the HRF Awards Reception on November 19 in Montreal, alongside the recipient of the prestigious Medal of Honour.
The HRF is eager to receive nominations of outstanding individuals whose research drives meaningful change in access, outcomes, and participation for underrepresented populations in Canada’s healthcare and research systems.
About the Health Research Foundation
The Health Research Foundation (HRF) of Innovative Medicines Canada is a non-profit organization that invests in Canadian academic health research and promotes the value of research-driven health innovation in Canada. The HRF is one of the leading private health foundations in the country and its contributions help prevent illness, treat disease, and improve Canada’s health-care systems. The organization is committed to addressing health challenges through research excellence, stakeholder partnerships and the advancement of public policy.
About Innovative Medicines Canada
Innovative Medicines Canada (IMC) is the national association representing Canada’s innovative pharmaceutical industry. The industry proudly supports over 100,000 high value jobs, contributes a total of $16 billion to the economy, sponsors the majority of clinical trials in Canada, and invests close to $3 billion in research and development each year. IMC advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians. The association and its members are committed to being solutions-oriented partners in Canada’s healthcare system and have contributed over $30 million towards applied health systems research through the Health Research Foundation (HRF). Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.
For further information: media@imc-mnc.ca
